pp65 RNA-LPs

pp65 RNA-LPs is an investigational mRNA-based cancer vaccine consisting of messenger RNA encoding the Cytomegalovirus (CMV) phosphoprotein 65 (pp65) encapsulated within lipid particles (LPs). Developed by researchers at the University of Florida, this immunotherapy is designed to treat malignancies that express CMV antigens, such as pediatric high-grade gliomas (pHGG). The mechanism involves the intravenous administration of the RNA-LPs, which primarily localize to the lungs and lymphoid organs to transfect antigen-presenting cells (APCs). These activated APCs then induce a robust, antigen-specific T-cell response and remodel the systemic and intratumoral immune environment to overcome immunosuppression. It is being studied both as a monotherapy and in combination with other tumor-specific mRNA-LPs in the RNA PRIME clinical trial.

Other names

pp65 RNA-LPspp-65 RNA-LPspp 65 RNA-LPsphosphoprotein 65 messenger RNA-lipid particlesphosphoprotein65 messenger RNA-lipid particlesphosphoprotein-65 messenger RNA-lipid particlespp65 mRNA-LPspp-65 mRNA-LPspp 65 mRNA-LPsCMV pp65 RNA-LPs